IMR-687 Continuing to Lower VOCs and Hospitalizations in SCD Patients

IMR-687 Continuing to Lower VOCs and Hospitalizations in SCD Patients

313851

IMR-687 Continuing to Lower VOCs and Hospitalizations in SCD Patients

IMR-687 (tovinontrine), an experimental oral therapy for sickle cell disease (SCD), reduced the rate of painful vaso-occlusive crisis (VOC), lowered hospitalization due to VOCs, and extended the time to a first VOC in SCD patients, according to new data from an open-label extension of a Phase 2 clinical trial. Another investigational SCD therapy, called IMR-261, also reduced VOCs in a mouse model of the disease. Both IMR-687 and IMR-261 are being developed by Imara. These…

You must be logged in to read/download the full post.